Galmed Pharmaceuticals Ltd. - Ordinary Shares (GLMD) analyst actions
Rating and price-target actions on GLMD in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the GLMD overview →
1 measured GLMD analyst action event.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Galmed Announces a delay in the initiation of its Primary Sclerosing Cholangitis (PSC) Phase 2a Study | Press release | +0.03% | +5.91% |
Keep exploring
More GLMD: earnings → · SEC filings → · GLMD overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Adaptimmune Therapeutics plc - American Depositary Shares (ADAP) | 159 | -1.17% | 27% |
| DURECT Corporation (DRRX) | 159 | +0.03% | 51% |
| GT Biopharma, Inc. (GTBP) | 159 | -0.91% | 32% |
| ImmuCell Corporation (ICCC) | 159 | 0.00% | 42% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.